Merck KGaA, Darmstadt, Germany to Acquire Silence Therapeutics, Strengthening Rare ...

Merck KGaA, Darmstadt, Germany announced an agreement to acquire Silence Therapeutics, a UK biotechnology firm with a phase 3-ready siRNA therapy for the rare disease polycythemia vera, for approximately $1.3 billion equity value. This acquisition enhances Merck's rare disease pipeline and global specialty healthcare innovation.

This Wire brief sits within Fusion42's coverage of Biotech.